



## **Spanish Ovarian Cancer Group - GEICO**

- ***was created in 1999***
- ***76 currently members of GEICO***
- ***promotes clinical studies in onco-gynaecological diseases***
- ***promotes development of scientific meetings on gynaecological oncology***
- ***every two years organizes an International Symposium entitled “Advanced Ovarian Cancer: Optimal Therapy Update.”***



## **CLINICAL TRIALS**

***Clinical Trial:* GEICO 0299 / EORTC 55981 / NSGO**

Randomized clinical trial of Paclitaxel / Epirubicin / Carboplatin in combination (TEC) vs Paclitaxel / Carboplatin (TC) in women treatment with advanced ovarian cancer. A randomized trial of Paclitaxel/Epirubicin/ Carboplatin Combination (TEC) versus Paclitaxel/Carboplatin (TC) in the treatment of women with Advanced Ovarian Cancer.

***Status:* CLOSED in August 2001**

***Recruitment:* 38 patients**



## CLINICAL TRIALS

*Clinical Trial:*    **GEICO 0199**

Randomized phase II clinical trial (with valuation of quality life) carboplatin vs combination taxol plus carboplatin in patients with platinum-sensitive relapses of ovarian cancer.

*Status:*            **CLOSED in December 2002**

*Recruitment:*    **81 patients**



## **CLINICAL TRIALS**

*Clinical Trial:*     **GEICO CO22**

Validation by GEICO of Caelyx in patients with epithelial ovarian cancer refractory to platinum.

*Status:*            **CLOSED in May 2003**

*Recruitment:*    **81 patients**



## CLINICAL TRIALS

*Clinical Trial:* **GEICO 0103**

A Phase II trial of fixed-dosed rate gemcitabine in platinum resistant ovarian cancer.

*Status:* **CLOSED in February 2005**

*Recruitment:* **41 patients**



## **CLINICAL TRIALS**

*Clinical Trial:*     **GEICO 0101**

Phase III clinical trial to evaluate the treatment with the combination cisplatin plus topotecan followed by paclitaxel plus carboplatin compared to paclitaxel plus carboplatin as a first line treatment in women who have recently been diagnosed with advanced ovarian epithelial cancer.

*Status:*            **CLOSED in June 2005**

*Recruitment:*    **129 patients**



## CLINICAL TRIALS

*Clinical Trial:*    **GEICO P02868 / GEIS 7**

Phase IV-II trial of Temozolide in a continuous oral administration scheme in the treatment of gynaecological sarcomas.

*Status:*            **CLOSED in September 2005**

*Recruitment:*    **14 patients GEICO / Total recruitment 33**



## CLINICAL TRIALS

*Clinical Trial:* **GEICO 0501**

Phase II exploratory study to evaluate the efficacy and safety of weekly topotecan in the treatment of persistent or recurring cervical cancer after failure of first line treatment with platinum derivatives.

*Status:* **CLOSED in March 2007**

*Recruitment:* **34 patients**



## CLINICAL TRIALS

*Clinical Trial:*    **GEICO 0104**

Randomised phase II study of the doublet carboplatin-gemcitabine followed by carboplatin-pacliaxel versus carboplatin-paclitaxel in patients with platinum-sensitive relapses of ovarian carcinoma, primary peritoneal carcinomatosis or carcinoma of the fallopian tubes.

*Status:*            **CLOSED in June 2007**

*Recruitment:*    **98 patients**



## CLINICAL TRIALS

*Clinical Trial:*    **ICON 7 / GEICO 0701**

A randomised, two-arm, multi-centre Gynaecologic Cancer InterGroup trial of adding bevacizumab to standard chemotherapy (carboplatin and paclitaxel) in patients with epithelial ovarian cancer.

*Status:*            **Closed**

*Recruitment:*    **41 patients**



## CLINICAL TRIALS

*Clinical Trial:* **MIMOSA**

Efficacy multicentre Trial of Immunotherapy Vaccination with abagomab to treat ovarian cancer patients.

*Status:* **Closed**

*Recruitment:* **103 patients**



## CLINICAL TRIALS

*Clinical Trial:*    **HECTOR (Intergroup Trial with NOGGO, AGO)**

Topotecan plus carboplatin versus standard therapy (paclitaxel plus carboplatin or gemcitabine plus carboplatin) in the therapy of patients with platinum-sensitive relapsed epithelial ovarian carcinoma, peritoneal carcinoma or tubal carcinoma.

*Status:*            **On Going**

*Recruitment:*    **1 patient**



## CLINICAL TRIALS

*Clinical Trial:*    **AGO-OVAR 16**

A Phase III study to evaluate the efficacy and safety of pazopanib versus Placebo in women who have undergone standard first line chemotherapy for epithelial ovarian, fallopian tube, or primary peritoneal cancer.

*Status:*            **Pending approvals**



## CLINICAL TRIALS

*Clinical Trial:* **NCIC-OV 21**

A Phase II/III study of intraperitoneal (IP) plus intravenous (IV) chemotherapy versus carboplatin plus paclitaxel in patients with epithelial ovarian cancer optimally debulked at surgery following neoadjuvant intravenous chemotherapy a Gynaecologic Cancer Intergroup (GCIG) Trial.

*Status:* **Agreed to Participate**



## CLINICAL TRIALS

*Title: OCTAVIA*

A single-arm Phase II clinical study of the combination of carboplatin and weekly paclitaxel plus bevacizumab as first-line treatment in patients with epithelial ovarian cancer

*Protocol Number MO22225*

*Status:* Pending Approval

## CLINICAL TRIALS

*Title:*           ***AURELIA***

*A multi-centre, open-label, randomised, two-arm Phase III trial of bevacizumab plus chemotherapy versus chemotherapy alone in patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer*

*Status:*           ***Agreed to participate***



## TRANSLATIONAL PROJECT

*Title:*           **TOPOISOMERASE II**

- Determination of topoisomerase II expression using immunohistochemistry in samples of ovarian cancer.
- Determination of topoisomerase II amplification using FISH in samples of ovarian cancer.

*Status:*           **ONGOING**



## **TRANSLATIONAL PROJECT**

***Title: GEICO 0801-T***

***Retrospective Study of Biomarkers in Epitelial Ovarian Cancer***

***Status: ONGOING.***



## **EARLY STAGE I, II A PROSPECTIVE REGISTER OF GEICO**

*Project:*            **Prospective register on early stages of EOC**

*From:*            **January of 1998    to: Actually open**

*Status:*           **645 patients**